Stock listing
Ribomic, Inc.
Selected listing: 4591 · TSE · JPY · JP
Ribomic, Inc. (Tokyo:4591), Health Technology. Latest release Oct 6, 2026: RIBOMIC Announces Interim Report on the Phase 2 Long-Term Clinical Trial…
- Ticker
- Tokyo:4591
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- Tokyo
- Currency
- JPY
About Ribomic, Inc.
Ribomic, Inc. is a public company listed under the ticker 4591, operating in the Japanese market. Ribomic focuses on developing innovative therapeutic solutions, leveraging its proprietary RNA-targeting technology.
Latest news from Ribomic, Inc.
RIBOMIC Announces Interim Report on the Phase 2 Long-Term Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
October 6, 2026
[Delayed]RIBOMIC Announces No Safety Concerns After Three Months of 1mg/kg Weekly Treatment with Umedaptanib Pegol in Achondroplasia Phase2 Study
September 29, 2026
RIBOMIC Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia
August 24, 2026
Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2026(Based on Japanese GAAP)
August 13, 2026
RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
July 1, 2026